{"product_id":"servier-pestle-analysis","title":"Servier PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, regulatory pressures, and rapid biotech innovation are shaping Servier’s strategic horizon—our concise PESTLE highlights risks and opportunities you can act on today. Buy the full PESTLE to access granular analysis, scenario-ready insights, and downloadable charts that save you research time and strengthen investment or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernments in the US and EU tightened price controls by late 2025, with US CMS targeting Medicare drug negotiation savings of an estimated $100–120 billion over 10 years and EU member states pursuing reference pricing and mandatory value assessments that cut list prices 10–25% in recent approvals.\u003c\/p\u003e\n\u003cp\u003eServier must balance margin pressure—estimated potential revenue impact of 8–15% for specialty portfolios—with ensuring patient access to innovative therapies through tiered pricing and patient-assistance programs.\u003c\/p\u003e\n\u003cp\u003eStrategic negotiation with payers and clear clinical-value dossiers are required: health technology assessments increasingly demand real-world evidence and cost-effectiveness thresholds often below €50,000 per QALY for non-oncology drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU Health Policy Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe EU’s drive to harmonize healthcare rules affects Servier’s product launches and supply-chain compliance; the EU Pharmaceutical Strategy and 2024 MDR updates raise regulatory alignment costs by an estimated 3–5% of revenues for mid-sized pharma firms. \u003c\/p\u003e\n\u003cp\u003eGrowing joint procurement (e.g., EU4Health pooled tenders covering ~€10bn 2024–27) offers Servier scale but risks centralized price pressure that could compress margins by 1–3 percentage points. \u003c\/p\u003e\n\u003cp\u003eServier must adapt regional manufacturing and registration strategies to align with evolving frameworks to protect its European market share (~30% of group sales in 2024). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions and shifting trade alliances continue to disrupt pharmaceutical supply chains and market access for international firms; in 2024 global trade tensions saw a 12% increase in export controls across key APIs-producing countries, affecting timelines and costs for companies like Servier.\u003c\/p\u003e\n\u003cp\u003eServier faces risks from tariffs and export restrictions on essential chemical precursors and finished products, with tariff spikes in 2023–24 raising input costs by an estimated 4–7% in affected routes.\u003c\/p\u003e\n\u003cp\u003eMaintaining a diversified manufacturing footprint—Servier’s 2025 target to source 40% of key intermediates from at least three regions—remains essential to mitigate political instability and ensure continuity of supply.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic-private partnerships and government grants drive pharma innovation; Servier benefited from EU Horizon 2020\/2021-like programs and France’s Crédit Impôt Recherche, which reduced R\u0026amp;D costs by up to 30%, supporting its oncology pipeline.\u003c\/p\u003e\n\u003cp\u003eServier depends on stable political support and targeted funding for oncology—France committed €7.5bn to health research 2024–2027—so shifts in leadership can reallocate grants, forcing agile R\u0026amp;D prioritization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic-private grants and tax credits lower Servier R\u0026amp;D expenses\u003c\/li\u003e\n\u003cli\u003eFrance’s €7.5bn health-research pledge (2024–2027) supports oncology\u003c\/li\u003e\n\u003cli\u003ePolicy shifts risk funding reallocation, requiring flexible R\u0026amp;D strategy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Access Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cppolitical movements toward universal health coverage and equity are increasing demand for affordable medications with who estimating billion people lacking full in pressuring servier to join state programs expanding access low-income regions.\u003e\u003cpservier faces obligations to participate in price-volume agreements and donation schemes that could lower ar margins the company reported revenue of so executives must balance social responsibility with sustaining r investment through\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO: 2bn without full UHC (2024)\u003c\/li\u003e\n\u003cli\u003eServier 2024 revenue €3.6bn\u003c\/li\u003e\n\u003cli\u003ePressure for price-volume\/state programs vs R\u0026amp;D funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pservier\u003e\u003c\/ppolitical\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier faces margin squeeze from US\/EU pricing \u0026amp; supply controls despite French support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressures—US Medicare negotiations (~$100–120bn savings\/10y), EU price cuts (10–25%) and HTA thresholds (~€50k\/QALY)—threaten Servier margins (potential 8–15% hit) while joint procurement (~€10bn 2024–27) and trade controls (+12% export controls 2024) raise supply risks; France’s €7.5bn health pledge and tax credits offset R\u0026amp;D costs (~30%), supporting a €3.6bn 2024 revenue base.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e€3.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Medicare savings target\u003c\/td\u003e\n\u003ctd\u003e$100–120bn\/10y\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU joint tenders\u003c\/td\u003e\n\u003ctd\u003e€10bn (2024–27)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTA threshold\u003c\/td\u003e\n\u003ctd\u003e~€50k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Servier across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven subpoints and region-specific examples to identify threats and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Servier's PESTLE into a concise, shareable brief—visually segmented by category for quick interpretation and easily dropped into presentations or strategy packs to support risk discussions and cross-team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Inflation Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent global inflation through 2025 has driven pharmaceutical input costs up: raw material prices rose ~12% YoY and energy costs surged ~20% in 2024, increasing Servier’s manufacturing expense base and skilled labor premiums; the group must absorb or manage these rises without materially raising drug prices to payers or patients. Efficient resource allocation and supply‑chain optimization are essential to protect margins amid higher operating costs and potential FX headwinds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Euro-reporting global group, Servier’s 2024 revenue exposed to FX showed a c.8–12% swing vs USD and select emerging currencies, meaning a 10% USD\/EUR move could alter reported revenue by roughly €200–300m; overseas clinical-trial costs in 2024 rose ~6% in local-currency terms due to depreciation in several EM currencies. Servier uses dynamic hedging and currency forwards\/options covering a significant portion of forecasted cash flows to stabilize P\u0026amp;L.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic growth in Southeast Asia (GDP growth ~4–5% in 2024) and Latin America (projected ~2.5–3% in 2024) expands market opportunities for Servier to increase market share as middle-class populations—estimated to grow by ~50 million in SEA and ~30 million in LATAM by 2025—gain better healthcare access and demand for specialty drugs; however, market entry requires substantial upfront investment and localized pricing strategies given variable per capita healthcare spending (e.g., SEA ~$500–$1,200; LATAM ~$800–$2,000 annually).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRD Capital Allocation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigh global interest rates in 2024–25 raised Servier’s weighted average cost of capital, pressuring financing for long-term R\u0026amp;D where ~25–30% of revenue is typically reinvested into innovation; Servier reported R\u0026amp;D spend of €1.2bn in 2024.\u003c\/p\u003e\n\u003cp\u003eTo preserve funding for late-stage trials costing €100–300m each, Servier balances increased use of internal cash flow with selective debt—net debt\/EBITDA targets tightened to ~2.0x in 2025—requiring strategic capital allocation across pipeline stages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend 2024: €1.2bn\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D reinvestment: ~25–30% revenue\u003c\/li\u003e\n\u003cli\u003eLate-stage trial cost: €100–300m\u003c\/li\u003e\n\u003cli\u003eNet debt\/EBITDA target ~2.0x (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Budget Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpnational health budgets face strain from aging demographics and rising tech costs oecd spending rose to of gdp on average in with public payers tightening coverage for high-cost therapies.\u003e\n\u003cpconsequently payers demand robust cost-effectiveness nice and hta bodies increasingly require icers showing long-term qaly gains delaying adoption of expensive innovations.\u003e\n\u003cpservier must produce real-world evidence and budget-impact models demonstrating per-patient cost offsets reduced hospitalizations or avoided comorbidity costs win reimbursement from cash-strapped public systems.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOECD avg health spend 9.6% GDP (2022)\u003c\/li\u003e\n\u003cli\u003eHTA focus on ICER\/QALY and long-term savings\u003c\/li\u003e\n\u003cli\u003eNeed RWE and budget-impact models to justify reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pservier\u003e\u003c\/pconsequently\u003e\u003c\/pnational\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma margins squeezed: input costs +12–20%, €1.2bn R\u0026amp;D, €200–300m FX hit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInflation and energy rose pharma input costs ~12–20% in 2024; FX moves (10% USD\/EUR) affect revenue by ~€200–300m; SEA\/LATAM GDP growth ~4–5%\/2.5–3% expands markets; R\u0026amp;D €1.2bn (25–30% rev) with late-stage trials €100–300m; net debt\/EBITDA target ~2.0x (2025); OECD health spend 9.6% GDP (2022); HTA focus on ICER\/QALY requires RWE.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost rise\u003c\/td\u003e\n\u003ctd\u003e~12–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX sensitivity\u003c\/td\u003e\n\u003ctd\u003e€200–300m per 10% USD\/EUR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\/EBITDA\u003c\/td\u003e\n\u003ctd\u003e~2.0x target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eServier PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Servier PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the content, layout, and analysis visible in the preview are identical to the downloadable file you’ll get instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751804416377,"sku":"servier-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/servier-pestle-analysis.png?v=1772234890","url":"https:\/\/matrixbcg.com\/products\/servier-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}